Phathom Pharmaceuticals Announces New CEO as Steven Basta Takes the Helm
Company - People | Apr 01, 2025 | Abingworth LLP
Phathom Pharmaceuticals has announced a change in leadership with Steven Basta being appointed as the new President and Chief Executive Officer, succeeding Terrie Curran. Basta brings extensive experience from his previous roles in biopharmaceutical and medical device industries, including serving as CEO at SaNOtize and Mahana Therapeutics. The transition is strategically aligned with Phathom’s goals to accelerate growth and enhance shareholder value, particularly in launching and expanding the commercial reach of its gastrointestinal treatments, such as VOQUEZNA. The company acknowledges Curran’s contributions in transitioning Phathom from a clinical stage to a commercial company and emphasizes its confidence in Basta's capability to further the company's ambitions. Phathom’s current focus remains on developing and commercializing VOQUEZNA for gastrointestinal diseases, although it acknowledges the potential risks involved in its commercial strategy.
Sectors
- Biopharmaceuticals
- Healthcare
Geography
- United States – Phathom Pharmaceuticals is based in the United States, and its operations, including the commercialization of VOQUEZNA, are primarily centered in this country.
Industry
- Biopharmaceuticals – The primary focus of both Phathom Pharmaceuticals and its new CEO, Steven Basta, is developing and commercializing novel biopharmaceutical treatments for gastrointestinal diseases.
- Healthcare – The article discusses the healthcare sector in its reference to developing treatments for gastrointestinal diseases and the commercial strategies of Phathom Pharmaceuticals.
Financials
- Not Specified – No specific financial figures like deal prices or revenues are mentioned in the article.
Participants
| Name | Role | Type | Description |
|---|---|---|---|
| Phathom Pharmaceuticals, Inc. | Company | Target | A biopharmaceutical company focused on gastrointestinal treatments, now under the new leadership of Steven Basta. |
| Steven Basta | Person | New CEO | Recently appointed as the President and CEO of Phathom Pharmaceuticals, succeeding Terrie Curran. |
| Terrie Curran | Person | Outgoing CEO | The former President and CEO of Phathom Pharmaceuticals who led the company from a clinical to a commercial stage. |
| Michael Cola | Person | Chairman | Chairman of Phathom Pharmaceuticals, responsible for welcoming Steven Basta and supporting the leadership transition. |
| Abingworth LLP | Company | Private Equity | A private equity firm presumably involved in the strategic developments at Phathom Pharmaceuticals. |